CELL THERAPY MANUFACTURING MARKET 2018-2030

Dissertation submitted in partial fulfillment of the requirement for the degree of

MASTER OF TECHNOLOGY

IN

BIOTECHNOLOGY

By

NATASHA THAKUR (133807)

UNDER THE GUIDANCE OF

Mr. Gaurav Chaudhary Ms. Simriti Gupta

Roots Analysis Pvt. Ltd.



JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY, WAKNAGHAT MAY 2018

CERTIFICATE

This is to certify that the work reported in the MTech. Thesis entitled "Cell Therapy Manufacturing Market 2018-2030" submitted by Natasha Thakur in partial fulfillment for the award of degree of MTech. in Biotechnology from Jaypee University of Information & Technology, Waknaghat has been carried out under my supervision. This work has not been submitted partially or wholly to any other University or Institute for the award of any other degree, diploma or such other titles.

Ms. Simriti Gupta Associate Roots Analysis Pvt. Ltd. Date:

DECLARATION

I hereby declare that the work reported in the MTech. thesis entitled "Cell Therapy Manufacturing Market 2018-2030" submitted at Jaypee University of Information Technology, Waknaghat is an authentic record of my work carried out under the supervision of Mr. Gaurav Chaudhary and Ms. Simriti Gupta. I have not submitted this work elsewhere for any other degree or diploma.

Natasha Thakur (133807) Department of Biotechnology & Bioinformatics JUIT, Waknaghat

Certified that the above statement made by the student is correct to the best of our knowledge and belief. Roots Analysis owns the copyright of the findings presented in this report. Under no circumstances should this information be shared with other third parties without the prior consent of the company.

Ms. Simriti Gupta Associate Roots Analysis Pvt. Ltd.

ACKNOWLEDGEMENT

This project is an outcome of continual work over and intellectual support from numerous sources. Therefore, I would like to express my sincere thanks to the people who have helped me the most throughout my project.

I owe my deepest gratitude to Mr. Gaurav Chaudhary, CEO, for providing me an opportunity to do internship at their prestigious organization. I am very grateful to Ms. Simriti Gupta for making it possible to carry out this project. Without hercontinuous optimism, enthusiasm, encouragement and support, this study may not have been accomplished as desired. Furthermore, I would also like to acknowledge with much appreciation the crucial role my esteemed advisors Mrs. Rupali Chaudhary and Mrs. Shivani Vadhera for their extremely valuable insights and direction at crucial points during the course of my project.

At last but not the least I am deeply grateful to all the members of Roots Analysis whorendered their help during the course of my training and my parents for their motivation, continual support and encouragement at all the stages of my life.

Natasha Thakur

(133807)

TABLE OF CONTENTS

		Number
	List of FIGURES	2
	List of ABBREVIATIONS	3
	ABSTRACT	4
	CHAPTER-1	5-6
	COMPANY PROFILE	
1.1	Company Overview	
1.2	Research Methodology	
	CHAPTER-2	7-13
	INTRODUCTION	
2.1	Chapter Overview	
2.2	Cell-Based Therapies: Introduction	
2.2.1	CELL-BASED THERAPIES: CLASSIFICATION	
2.2.2	Cell-Based Therapies: Current Market Landscape	
2.3	Cell Therapy Manufacturing: An Introduction	
2.3.1	Cell Therapy Manufacturing: Manufacturing models	
2.3.2	Cell Therapy Manufacturing: Types of manufacturers	
2.4	Cell-Based Therapies: Key Manufacturing Challenges	
	CHAPTER-3	14-16
	MARKET OVERVIEW	
3.1	Chapter Overview	

3.2 Overall Market Landscape

3.3	Database Building	
	CHAPTER-4	17-19
	ROADMAPS: STRATEGIES TO OVERCOME EXISTING	
	CHALLENGES	
4.1	Chapter Overview	
4.2	Roadmap for the US	
4.3	Roadmap for Europe	
4.4	Roadmap for Asia Pacific	
	CHAPTER-5	20-23
	INDUSTRY PLAYERS	
5.1	Chapter Overview	
5.2	Example of an Industry Profile	
	CHAPTER-6	24-26
	NON-INDUSTRY PLAYERS	
6.1	Chapter Overview	
6.2	Example of Non-Industry Profile	
	CHAPTER-7	27-29
	NON-PROFIT ORGANIZATIONS	
7.1	Chapter Overview	
7.2	Non-Profit Organizations	
7.3	Example of Non-Profit Organization	
7.4	International Societies	
	CHAPTER-8	30-31
	REGULATORY LANDSCAPE	

8.1	Chapter Overview	
8.2	Regulatory Systems	
	CHAPTER-9	32-33
	RECENT DEVELOPMENTS	
9.1	Chapter Overview	
9.2	Partnerships	
9.3	Expansions	
	CHAPTER-10	34-36
	PRIMARY RESEARCH	
10.1	Overview	
10.2	Interview Contacts	
	CHAPTER-11	37-40
	ADDITIONAL PROJECTS	
11.1	Gene Therapy	
11.1.1	Collecting KOLs	
11.1.2	Short Profiling of key industry players	
11.2	Undruggable Cancer Targets	
11.2.1	Bulls Eye	
11.2.2	Regional Analysis	
	CHAPTER-12	41
	REFERENCES	

LIST OF FIGURES

Figure	Caption	Page
Number		Number
2.1	Highlightsthe different classes of ATMPs	8
2.2	Represents cell-based therapies that have been approved /	9
	launched across different countries	
2.3	Represents the process model for centralized manufacturing	10
2.4	Represents the process model for decentralized	11
	manufacturing	
2.5	Represents the types of manufacturers involved in cell	12
	therapy manufacturing	
2.6	Highlights the major roadblocks and key growth drivers of	13
	the cell therapy market	
3.1	Represents the database of the cell therapy manufacturing	15
	market	
3.2	Provides information on the various parameters captured in	16
	the database	
4.1	Represents the roadmap designed for the United States	18
4.2	Represents the roadmap designed for Asia Pacific	19
5.1	Represents the company overview section in an industry	21
	profile	
5.2	Represents the service portfolio section in an industry	22
	profile	
5.3	Represents the manufacturing capabilities section in an	23
	industry profile	
6.1	Represents the overview section in a non-industry profile	25
6.2	Represents the service portfolio section in a non-industry	25
	profile	
6.3	Represents the manufacturing capabilities section in a non-	26
	industry profile	
7.1	Represents the list of non-profit organizations	27

7.2	Represents an overview of a Non-Profit Organization:	28
	CellCAN	
7.3	Represents the list of various international gene and cell	29
	therapy societies	
8.1	Represents the regulatory considerations for cell therapies	31
9.1	Provides information on collaborations / partnerships of key	32
	industry players	
9.2	Provides information on expansion that the industry is	33
	undergoing for manufacturing of cell therapies	
10.1	Highlights the various contacts of the key industry / non-	35
	industry players	
10.2	Represents the Interview Transcript for cell therapy	36
	manufacturing market project	
11.1	Represents the list of Key Opinion Leaders engaged in the	37
	field of gene therapy	
11.2	Represents the brief profiling of two industry players	38
	engaged in the field of gene therapy	
11.3	Bulls Eye Representation	39
11.4	Regional Analysis	40

LIST OF ABBREVIATIONS

ASGCT	American Society of Gene and Cell Therapy
ATMPs	Advanced Therapy Medicinal Products
cGMP	Current Good Manufacturing Practices
ESCs	Embryonic Stem Cells
GRA	Georgia Research Alliance
iPSCs	Induced Pluripotent Stem Cells
KOLs	Key Opinion Leaders
MSCs	Mesenchymal Stem Cells / Mesenchymal Stromal Cells
NCMC	National Cell Manufacturing Consortium
NIST	National Institute of Standards and Technology
NK Cells	Natural Killer Cells
Tregs	Regulatory T-cells

ABSTRACT

The project "*Cell Therapy Manufacturing Market, 2018-2030*" provides an extensive study of the rapidly growing market of cell therapy manufacturing and focuses both on contract manufacturers and cell therapy developers with in-house manufacturing facilities. Cell therapy is based on the premise that the patient's own cells (autologous) or those from a healthy donor (allogeneic) can be programmed to combat certain types of diseases when they are re-infused into the body. These therapies are anticipated to emerge as viable alternatives to conventional treatment options. The scope of this project primarily includes manufacturing of advanced therapy medicinal products (ATMPs) that involve the use of immune cells such as T-cells, Tregs, dendritic cells, tumor cells and NK cells, and stem cells (iPSCs).Several players, including cell therapy developers, research institutes, contract manufacturing organizations, and government and non-profit organizations, are playing a critical role in the development and manufacturing of these cell therapies.

During the course of my on-job training, I worked on different modules of the project. These include the introduction of cell therapy manufacturing, pipeline of several players involved in this field, detailed profiling of those players, information regarding collaborations and partnerships, roadmaps, regulatory landscape, non-profit organizations, primary research and automation in cell therapy manufacturing. Apart from this, I contributed in two additional projects namely, Gene Therapy and Undruggable Cancer Targets where I covered short profiling of companies, worked on different representations and collected KOLs.

COMPANY PROFILE



1.1 Company Overview

Roots Analysis Pvt. Ltd. is a business research and consulting firm, which specializes in providing in-depth business research and consulting services for bio/pharmaceutical industry. Focused on providing an informed and impartial view on key challenges facing the industry, the research is primarily driven by an in-depth analysis covering the following parameters [1]:

- Research and development
- Technology evolution
- Existing market landscape
- Future Commercial potential
- Regulatory concerns
- Regional growth drivers
- Risks and opportunities

The firmhas expertise in analyzing areas that have lacked quality research so far or require more focused understanding within the broader industry. Apart from writing reports on identified areas, the company also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The business reports highlight trends ranging from commercial success / potential, technological developments and future outlook built around opportunities and threats.

The company majorly focus on areas spanning the following domains:

- Therapeutic segments
- Emerging technologies
- Medical devices
- Drug Delivery
- Clinical Trials

1.2 Research Methodology

The data presented in the reports has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts' views

INTRODUCTION

2.1Chapter Overview

Cell-based therapies involve the use of different types of cells for achieving a desired therapeutic benefit. These cells can be immune cells, such as antigen presenting cells (dendritic cells and macrophages), natural killer cells and lymphocytes (T-cells), adult stem cells / tissues (mesenchymal cells, hematopoietic progenitor cells), embryonic stem cells, induced pluripotent stem cells, and other advanced therapy medical products, such as chondrocytes. As the increasing number of cell therapy products progress through various phases of clinical development, the demand for their manufacturing is likely to become stronger in the near future.Cell therapies are based on the premise that the patient's own cells (autologous), or those from a healthy donor (allogeneic), can be genetically re-programmed to combat various diseases. As anticipated, these therapies have emerged as viable alternatives to traditional treatment options, such as small molecule drugs. The last two decades have witnessed a number of advances in cell therapies, particularly in their manufacturing processes. However, even the latest and most promising advances in modern medicine have their own set of challenges and risks, which need to be addressed to ensure continued growth.

Manufacturing of cell therapies is a complex and logistically challenging multi-step process. It involves high capital costs, culturing of cells for several days in regulated environment and management by skilled personnel. Inception of cell therapies has introduced the concept of *one batch run equals to one product*. Currently, for the purpose of manufacturing, cell-based products for clinical trials, companies / academia are utilizing open lab-based systems; however, commercial manufacturing of such therapies demands automated and scalable closed systems as well as robust, reproducible and standardized procedures. Despite multiple challenges related to manufacturing of thesetherapies, several stakeholders, including service providers, are continuously investing in efforts to combat specific roadblocks.

2.2 Cell-Based Therapies: Introduction

The American Society of Gene and Cell Therapy (ASGCT) defines cell therapy as a therapeutic modality that contains either normal or modified cells, which are administered to patients for the treatment of various diseases. In this form of therapy, patients are injected with living and intact human cells that are deemed to provide therapeutic benefit. The transplanted cells have been shown to help in restoring or repairing the function of cells, which are damaged or have ceased functioning due to disease. The main goal of cell therapy is to target the root cause of the disease at the cellular level [2].

2.2.1 Cell-Based Therapies: Classification

The EU regulatory authority provides a system of classification on the basis of the extent of genetic manipulation required for homologous use (such as transplants / transfusions) and heterogeneous use (such as ATMPs) with respect to quality, safety and efficacy of the therapeutic modality. As per the Article (2) (a) of Regulation (EC) No.1394/2007, ATMPs are defined as therapeutic products that can exert pharmacological, immunological or metabolic action to restore, correct or modify physiological functions in order to treat diseases [3].




Figure 2.1 Highlights the different classes of ATMPs

/I - Intro	duction 1234 - N	licrosoft Word	Table Tools						
ut Re	eferences Mailing	js Review	View Design	Layout					
≀oman	• 12 • A A			I • 11	AaBbC 1.1	l. A∦ 1.1.	1. / 1.1.1.1	. 1.1.1.1.	1.1.1.1. Aa
· abe >	x² Aa ⁺		▋▇▏▓▋▖▓▖▝▁	Chapter H	1 Figure H L	evel 1 Leve	el 2 Level 3	Level 4	Level 5 1 N
Fo	ont	5	Paragraph	G.			Styles		
I • •	ⅢL + I + Z + I	II 3 · i · 4 ·	Ⅲ ・5 ・1 ・6 ・1	II 7 · · · 8 ·	III · 9 · · · 10	■ (+ 11 +)	12 · · · 13	1 · · 14 · · · ·	II5 · · · 16 · I
S. No	Name of the Product	Approval Year	Type of Cells Used	Type of Therapy	Indication	Marketed	Company	Manufacturing Location	Manufacturer Type
1	Kymriah ¹³ (tisag enlecleucel)	2017	CAR positive T- cells	Autologous	B-cell precursor acute lymphoblastic leukemia	US, EU	Novartis Pharmaceuti cals	US	In-house
2	Yescarta ¹⁴ (axicabtagenec iloleucel)	2017	T-cells	Autologous	B-cell lymphoma	US, EU	Kite Pharma (a Gilead company)	US	In-house
3	Strimvelis	2016	CD34+bone marrow HSCs	Autologous	ADA-SCID	EU	GlaxoSmith Kline	Italy	Contract
4	Zalmoxis ¹⁵	201616	T-cells	Allogeneic	High risk hematological cancers	EU	<u>MolMed</u>	Italy	In-house
5	HeartSheet ¹⁷	2015	Skeletal myoblasts	Autologous	Heart failure	Japan	Terumo	Japan	In-house

2.2.2 Cell-Based Therapies: Current Market Landscape

Figure 2.2 Represents cell-based therapies that have been approved / launched across different countries

2.3 Cell Therapy Manufacturing: An Introduction

Manufacturing biologics and cell therapies is considerably complex as compared to small molecule drugs. The production of biological products as therapeutic interventions is likely to be influenced by several factors.More specifically, the major considerations that need to be addressed for manufacturing cell therapies are listed below:

- Ethical consent and clearance
- Identification of scalable approaches for separation and purification
- Development and optimization of cost-effective and chemically modified media
- Establishment of closed automated systems for manufacturing of cell therapies for multiple patients at the same time

2.3.1 Cell Therapy Manufacturing: Manufacturing Models

There are two types of manufacturing models:

- Centralized Manufacturing Model
- Decentralized Manufacturing Model

				CTM - Introd	luction 1234				
Review	View	Help	Q Search						(K)
* ¹ / ₂ + ¹ / ₂ +	€≣ →≣	2↓ ¶	1. A	AaBbC	1.1. AA	1.1.1. 2	1.1.1.1.	1.1.1.1.	1.1.1.1.
$\equiv \equiv \equiv$	\$≣ - ≜	- 💷 -	Chapter H	¶ Figure H	Level 1	Level 2	Level 3	Level 4	Level 5
	graph		G.					Styles	

1.4.1. CENTRALIZED MANUFACTURING MODEL

The concept of manufacturing the pharmaceutical products through conventional methodologies follow the centralized manufacturing approach. Most of the allogeneic cell therapies in development phase implement centralized manufacturing model which consists of a single facility where the process of production and distribution of therapeutic products are carried out simultaneously. According to a non-profit organization (APQC), companies following centralized approach of manufacturing are in benefit as they have profit of about 3% in the manufacturing cost as compared to the decentralized companies.^{40,41}

Figure 3.3 represents the sequential steps followed in the centralized manufacturing approach.




Figure 3.3 Centralized Manufacturing: Process Model

Figure 2.3 Represents the process model for centralized manufacturing

						CTM - Introd	luction 1234				-
eview	View	Help	Ç) Searcl	h						7)
* ^{\$} a+ i-	€≣→≣	₽↓	¶	1.	\mathbf{A}_{t}	AaBbC	1.1. A#	1.1.1.	1.1.1.1.	1.1.1.1.	1.1.1
≣ :	;≣ - ≞	• 💷 ·	•	Chapt	er H	¶ Figure H	Level 1	Level 2	Level 3	Level 4	Level
Parag	raph		Б							Styles	

1.4.2. DECENTRALIZED MANUFACTURING MODEL

Decentralized model offers its platform of manufacturing to those health care therapies that have high degree of personalization. Autologous or personalized cell therapy demands a scale-out approach in order to make sure that the patient material is completely isolated and is prevented from cross contamination. Decentralized manufacturing, also known as, redistributed manufacturing turned the cell therapy manufacturing approach upside down by overcoming the major challenge of distribution of high volume goods. This approach split their production processes across different locations, sites and geographic regions. Decentralized model of manufacturing imposes significant changes in the organizational structure, bringing out the hidden challenges that must be addressed. ^{43,44} Figure 3.4 represents the process model of decentralized manufacturing approach.

Figure 3.4 Decentralized Manufacturing: Process Model




Figure 2.4 Represents the process model for decentralized manufacturing

2.3.2 Cell Therapy Manufacturing: Types of manufacturers

Most cell therapy developers prefer to collaborate with contract manufacturers and outsource their manufacturing requirements. At the same time, larger and more established firms choose to invest in developing in-house manufacturing capabilities. Despite the exorbitant costs, the unavoidable need for elaborate manufacturing facilities, stringent regulatory scenario and other drawbacks, there is a growing interest in this emerging field, and a number of companies have recently stepped in.



Figure 3.5 Cell Therapy Manufacturing: Types of Manufacturers



Figure 2.5 Represents the types of manufacturers involved in cell therapy manufacturing

2.4 Cell-Based Therapies: Key Manufacturing Challenges

Some of the key challenges faced by cell therapy manufacturers are [4]:

- Sophisticated equipment is required for the relocation, transport and multi-site distribution of cell therapy products. Therefore, the facilities where cell-based therapies are to be developed and manufactured should be established at easily accessible locations, such as near airports for overseas transitions.
- Setting up cGMP facilities and obtaining the necessary qualifications and certifications is not only challenging, but also requires heavy investments. Moreover, cell production facilities should also be equipped with proper storage rooms, clean rooms, cryopreservation rooms and have various other cell processing capabilities as well.
- Contamination is a key concern when it comes to manufacturing cell therapy products. To overcome this, manufacturers are required to modify their current procedures to incorporate closed manufacturing systems.

	Mailing	gs Revie	ew View	, He	elp ¹	🗘 Searc		CTM - Introd	uction 1234					o—
•	۶ :	= • = •	• <u>-</u> •	● ≣ \$	↓ ¶	1.	\mathbf{A}_{t}	AaBbC	1.1. A#	1.1.1. 2	1.1.1.1.	1.1.1.1.	1.1.1.1.	AaBbO
- /	4 ≣ Ģ		■ ‡≣ - Paragraph	Å •	- E		ter H	1 Figure H	Level 1	Level 2	Level 3	Level 4 Styles	Level 5	¶ Norm

Figure 3.6 highlights the major roadblocks and key growth drivers of the cell therapy market.




Figure 3.6 Cell Therapy: Challenges and Drivers

Figure 2.6 Highlights the major roadblocks and key growth drivers of the cell therapy market

MARKET OVERVIEW

3.1Chapter Overview

The use of live cells for therapeutic purposes can be traced back to 1968, when patients were first successfully treated with allogeneic human hematopoietic stem cell transplants. This practice has now become an integral part of clinical procedures in the space of bone marrow regeneration. However, two decades later, the true potential of stem cells remained untapped until stem cells were tested for their use as therapeutic agents for regenerating skeletal tissues. Prochymal, aMSC therapy developed by Osiris Therapeutics, was amongst the first cellular therapies to be approved in Canada and New Zealand [5].

3.2 Overall Market Landscape

Cell therapies have shown positive clinical results and potential to treat life threatening diseases, such as cancer, autoimmune disorders and infectious diseases. Such benefits have outweighed the drawbacks associated with the domain that primarily comprise complex, time consuming and tedious manufacturing processes. This domain has attracted several research institutes and companies to invest time and money. In order to meet the growing demand of increased number of clinical trials and improve the manufacturing processes, more and more organizations are contributing to the space by setting-up capabilities to manufacture cell-based therapies. In this project, we identified over several organizations, including industry stakeholders and academic players that are actively involved in the production of cellular therapies.

3.3Database Building

Database is a list of companies / devices / technologies that has been created from multiple sources including public records, surveys, primary research, and company sources. It serves as the most important stepin the process of report writing. Hence, it must be robust, exhaustive and finely structured.

Αι	itoSave 💿 Off	ਜ਼ 5 - ੋ			с	ell Therapy Manufacturing	Database Final (15 May)	locked - Excel	
File	Home	Insert Page	Layout Form	ulas Data F	eview View Help 🛛 Search				
Ê	K Cut	Times Ne	w Roma 🔻 10	- A A = =	≡ 🗞 - 👌 Wrap Text	General 🔻		Normal	Bad
Paste	Format Pa	inter B I	u - 🖽 - 🕹	• <u>A</u> • = =	🚎 🚎 🗮 Merge & Center 🔹	\$ • % • \$.0 .00	Conditional Format as Formatting - Table -	Good	Neutral
	Clipboard	G.	Font	Es.	Alignment 5	Number 🕞	Tornatang Table	Styles	
B34	-	- × ×	<i>f_x</i> =B33+1						
	В	С	D	E	F		G	н	1
2	S.No.	Employee Ba	Founding Y	Headquarters	Company Name		Industry / Non-I	Location (M: N	o. of Facili
3			<u> </u>						
4									
5	1	51-200 empl	2006	NoáinNavarra	3P Biopharmaceuticals		Industry	EU (Spain) 1	
6	2	201-500 emp	2008	Abingdon, Oxf	Adaptimmune	•	Industry	US 1	
7	3		1810	Connecticut, C	Advanced Cell Therapy Laborate	ory, Yale School of I	Non-Industry	US 1	
В	4	2-10 employe	2016	London	Advent Bioservices		Industry	UK (London) 1	
9	5				AGC (Asahi Glass Company)		Industry	Asia (Japan) U	ndisclosed
0	6		2009	Canada	Alberta Cell Therapy Manufactu	uring	Non-Industry	Canada 1	
1	7	11-50 emplo	1999	San Diego, CA	Allele Biotechnology & Pharma	aceuticals	Industry	US 1	
2	8		2008	Sevilla, Spain	Andalusian Initiative of Advance	ed Therapies	Non-Industry	EU (Spain) 1	0
3	9		2000	Seoul, South K	Anterogen		Industry	Asia (Korea) 1	
4	10	11-50 emplo	2007	Ottobrunn	Apceth Biopharma		Industry	EU (Germany 2	
5	11	51-200 empl	1997		Argos Therapeutics		Industry	US 2	
6	12	http://www.co	2012	Fremont, Cali	Asterias Biotherapeutics		Industry	US 1	
7	13	51-200 emplo	2012	South San Fran	Atara Biotherapeutics	•	Industry	US 1	
8	14		2014	Saint Herblain	Atlantic Bio GMP		Industry	EU (France) 1	
9		201-500 emp		Kvistgaard, De	Bavarian Nordic		Industry	EU (Denmark 1	
20		51-200 empl		Houston, Texa	Bellicum Phamaceuticals			US 1	
21		2-10 employe		Saint Priest, Fi	<u>Bio Elpida</u>		Industry	EU (France) 1	
22	18	2-10 employe	2008	Prague	Bioinova sro		Industry	EU (Czech Re 1	
23	19				Biological and Cellular GMP M	Ianufacturing Facility	Non-Industry	US 1	
•	20	heet1 Sheet4	Sheet3	Sheet2 (+)					_

Figure 3.1Represents the database of the cell therapy manufacturing market

For building a database, several parameters were selected in with respect to the scope of the project. Cell therapy manufacturing market is a service-based project, hence all the industry, non-industry players involved in manufacturing of cell therapies were captured along with some of the basic information about the organization. For example, the founding year of the company, total number of employees in the company and their headquarters. Other key parameters that were captured in the project are listed below:

- Type of organization (industry / non-industry player)
- Location of the manufacturing facility
- Total number of manufacturing facilities
- Type of cells the company is manufacturing
- Type of manufacturer
- GMP-complaint
- Scale of operation

Cell Therapy Manufacturing Database Final (15 May) locked - Excel	Shivam Kumar 🖻 —
eview View Help Q Search	
Wrap Text General Image: Conditional Format as Formating T Tables Normal Bad Image: Sector and the sect	Clear Filler Solect Filler Filler
Alignment I Number I Styles	Cells Editing

F	G	н	0	Р	Q	R	S
Company Name	Industry / Non-	I Location (M					Type of Manufacturer
			Adult Sten	hESCs	iPSCs	Others (in	cluding tumor cells)
3P Biopharmaceuticals	Industry	EU (Spain)	✓			×	CDMO
Adaptimmune	Industry	US					In-house
Advanced Cell Therapy Laboratory, Yale School of	Non-Industry	US	✓	✓	\checkmark		In-house
Advent Bioservices	Industry	UK (London)					СМО
AGC (Asahi Glass Company)	Industry	Asia (Japan)	1				СМО
Alberta Cell Therapy Manufacturing	Non-Industry	Canada					СМО
Allele Biotechnology & Pharmaceuticals	Industry	US			✓		CMO
Andalusian Initiative of Advanced Therapies	Non-Industry	EU (Spain)	✓		✓		СМО
Anterogen	Industry	Asia (Korea)	✓				In-house
Apceth Biopharma	Industry	EU (Germany	~		~		In-house; CDMO
Argos Therapeutics	Industry	US					In-house
Asterias Biotherapeutics	Industry	US		✓			In-house
Atara Biotherapeutics	Industry	US					In-house
Atlantic Bio GMP	Industry	EU (France)	✓				СМО
Bavarian Nordic	Industry	EU (Denmark					In-house
Bellicum Phamaceuticals	Industry	US					In-house
Bio Elpida	Industry	EU (France)	✓			1	CDMO
Bioinova sro	Industry	EU (Czech Re	~				СМО
Biological and Cellular GMP Manufacturing Facility		US	✓	✓	\checkmark	Act	CMO; In-House
	lе е .	ETT (0	1			Go t	o Settings to activate Window

Figure 3.2Provides information on the various parameters captured in the database

ROADMAPS: STRATEGIES TO OVERCOME EXISTING CHALLENGES

4.1Chapter Overview

Cellular therapies, such as T-cell immunotherapies, dendritic cell vaccines and stem cell-based therapies, have evolved considerably over the past few years. Although some of these therapies have been approved in different regions of the world, there are certain challenges that need to be worked on in order to realize their full potential. For this, different organizations have developed comprehensive roadmaps, predicting the anticipated movement of these therapies from clinical trials to commercial launch. Such roadmaps differ for different geographiesand highlight the role of different stakeholders in the industry, such as pharmaceutical companies, academic institutions and government agencies, and their involvement in building a seamless process flow related to the development, production and launch of these therapies.

In my project, we have included roadmap for three geographies:

- Roadmap for the United States
- Roadmap for Europe
- Roadmap for Asia Pacific

4.2Roadmap for the US

In February 2016, the National Cell Manufacturing Consortium (NCMC), the Georgia Research Alliance (GRA) and the Georgia Institute of Technology (Georgia Tech) published a roadmap that identified the challenges associated with cell therapy manufacturing. A revised version of these strategies was published in July 2017 with the support of National Institute of Standards and Technology (NIST). The roadmap highlighted possible strategies, which, if implemented in the coming 10 years, are likely

to facilitate large scale, cost-effective and reproducible manufacturing of high quality cells [6].

CTM- Roadmaps 1234	Tabl	e Tools							
ences Mailings Review View	Help Design	Layout Q S	Gearch						
Aa • 🏘 🗄 • 🗄 • ⁵╦ • । 🗺	. 2↓ ¶ 1.	A: AaBbC	1.1. AA	1.1.1. 4	1.1.1.1.	1.1.1.1.	1.1.1.1.	AaBbCcI	AaBbCo
<u>*</u> - <u>A</u> - <u>≡</u> ≡ ≡ ≡ ‡ -	🕭 - 🖂 - Chap	ter H 1 Figure H	Level 1	Level 2	Level 3	Level 4	Level 5	1 Normal	Normal
Paragraph	5					Styles			
Figure 5.1 Cell Th	erany Mar	ufacturir	ισ· Roa	dman	for the				
	crupj mu	i di la contra i	5 110		Term	Mid Terr	n Le	ong Term	
Description					-2018)	(2019-202		022-2025)	
Cell Processing									
Separation Techniques (approaches fo	or						
purification and separati	/						_		
Culture Media Advances	` 1	1							
inexpensive, chemically									
systems that do not conta		1	/						
Cell Expansion Equipme with increased capacity,									
systems that enable onlin			logy (11)						
Cell Expansion Equipme			closed						
systems that enable para									
samples)		5 1							
Cell Expansion, Modific	ation and Differ	entiation Meth	nods						
(Development of scalabl									
Cell Expansion, Modific									
(Establishment of approa									
efficiency genetically en		at can elicit th	le						
anticipated therapeutic re Cell Preservation, Distri	1 /	n dlin a							
Product Tracking System		0	oting and						
tracking products and pa	· · · · · · · · · · · · · · · · · · ·								
multiproduct production		i securery in a							
Storage Infrastructure (1		infrastructure	and						
methods for long-term st									
Advanced Cryopreserval									
related to the response of									

Figure 4.1 Represents the roadmap designed for the United States

4.3 Roadmap for Europe

In November 2016, an Advanced Therapies Manufacturing Action Plan was published by the Medicines Manufacturing Industry Partnerships with recommendations to progress the manufacturing initiatives related to ATMPs in the UK. The roadmap was designed to improve and increase the economic aspect within the healthcare segment. The key takeaways from the roadmap include strengthening and securing a competitive international landscape to captivate investment and applying a simple engagement process to target and seize international mobile investments [7].

4.4 Roadmap for Asia Pacific

	CTM- Roadmaps 1234										
Review View	Help	♀ Search						U Y			
$\underbrace{\overset{1}{\overset{1}{\overset{1}{\overset{1}{\overset{1}{\overset{1}{\overset{1}{1$	Â↓	¶ 1. A	AaBbC	1.1. A#	1.1.1. 2	1.1.1.1.	1.1.1.1.	1.1.1.1.			
= = 💷 - 🕭	2 - 💷 -	Chapter H	1 Figure H	Level 1	Level 2	Level 3	Level 4	Level 5			
Paragraph		G					Styles				

1.3.2. ASIA PACIFIC

The Asia-Pacific Economic Cooperation (APEC) established the Life Sciences Innovation Forum (LSIF) in 2002. LSIF, which creates a policy environment for government, industry and academia in the life sciences segment, founded a regulatory committee, known as Regulatory Harmonization Steering Committee (RHSC), in 2009. The key objectives of the committee are to identify international standards and guidelines and propose them to APEC countries and facilitate the implementation of these guidelines through education and workshop-mediated support.¹¹

In March 2012, the APEC LSIF RHSC acknowledged a new Priority Work Area for promoting regulatory conjunction in APEC countries to regulate cell and tissue-based therapies. The near-term goal of the Priority Work Area was to establish a synchronized understanding of cell and tissue-based therapies and facilitate the formation of training programs. The long-term goal is to stimulate future convergence of technological requirements. Subsequently, the committee and the Singapore Health Sciences Authority (HSA) published a roadmap in July 2013. The roadmap outlined the project scope, roles and responsibilities, and expected milestones and deliverables by 2020 (specific to regulatory guidelines).^{12, 13} Figure 5.3 provides an overview of the timelines proposed in the <u>aforementioned roadmap</u>.

Figure 5.3 Cell Therapy Manufacturing: Roadmap for the APEC

Description	Near Term (2012-2014)	Mid-Term (2015-2018)	Long Term (2019-2020)
Initial Assessment of current manufacturing practices			, í
Training of workforce			
Assessment of Training			
Training to reach the goal and further recommendation for regulatory convergence			

Figure 4.2 Represents the roadmap designed for Asia Pacific

INDUSTRY PLAYERS

5.1Chapter Overview

The chapter comprises of detailed profiles of companies that offer services for the development and manufacturing of cell therapies.We have focused primarily on the companies offer a well-established suite of services including product development and manufacturing. In addition, these players have significantly contributed in the advancement of cell therapies by collaborating with other stakeholders in the industry. Each profile includes information on the key features of the facilities, area / infrastructure, regulatory licenses and partnerships inked by the contract manufacturers.

The following companies have been profiled in this project:

- Nikon Cell Innovation
- Cell Therapies
- Cryosite
- Cognate BioServices
- MaSTherCell
- Japan Tissue Engineering (J-TEC)
- Medinet
- KBI Biopharma
- BioNTech Innovative Manufacturing Services
- Fujifilm Cellular Dynamics
- Brammer Bio
- WuXi Advanced Therapies
- Cell and Gene Therapy Catapult
- CELLforCURE
- Lonza
- PCT, A Hitachi Group Company
- Roslin Cells Therapies

Waisman Biomanufacturing

5.2Example of an Industry Profile: Cell and Gene Therapy Catapult

es - Saved to \\172.16.1.2\Natasha	Table Tools	•
Mailings Review View Help	Design Layout Q Search	(K)
▾│१ 🗧 🗄 🛨 ་ོོོ་་│ 🖅 🕅	1. A: AaBbC 1.1. A# 1.1.1. 1 1.1.1.1. 1.1.1.1.	1.1.1.1. AaBbCcI
· 🔺 📄 🚍 🚍 📄 🇯 • 🗎 •		Level 5 1 Normal
ធ Paragraph	Styles	

The company was founded in 2012 with the vision to develop, deliver and commercialize scientific methodologies to bridge the gaps in manufacturing cell and gene therapy products. The company aims to advance cell therapy products in clinical studies <u>in order to</u> limit risks associated with further investment. According to the company, this can be achieved by providing technical expertise and infrastructure for manufacturing cell and gene therapy products. The company also offers services for guidance on regulatory issues to ensure the safe entry of products in clinical trials, <u>and also</u> provides platform for facilitating global collaborations. The company was renamed as Cell and Gene Therapy Catapult in February 2016.³

Table 7.1 provides a brief overview of Cell and Gene Therapy Catapult.

Key Parameters	Description	
Headquarters	London, UK	
Year of Establishment	20124	
Number of Employees	More than 130 ⁵	
Services	 Product development Process development Commercial / clinical manufacturing Clinical and regulatory support 	
Manufacturing Site(s)	Guy's Hospital (viral vector lab) and Stevenage, UK6	

Table 7.1 Cell and Gene Therapy Catapult: Company Overview

Figure 5.1 Represents the company overview section in an industry profile

- Sav	ved to \\	172.16.1.2\N	Vatasha			Table	Tools						-	
Mai	ilings	Review	View	Help	D	esign	Layo	ut 🖓	Search					
R	: = -	$\frac{1}{2}$ $+$ $\frac{1}{2}$ $+$ $\frac{1}{1}$ $+$	€≣⇒	≣ 2 ↓	¶	1.	\mathbf{A}_{ℓ}	AaBb	C 1.1. A A	1.1.1. 1	1.1.1.1.	1.1.1.1.	1.1.1.1.	AaBbCcI
A -	= =	= =	\$≣ -	ð - 🔛	-	Chapt	er H 1	ĭ Figure ⊦	I Level 1	Level 2	Level 3	Level 4	Level 5	¶ Normal
E.		Para	graph		E.							Styles		

1.2.2. SERVICE PORTFOLIO

The firm provides a wide range of services, which include R&D services, contract research, product development and manufacturing, and process development. Figure 7.1 provides a pictorial representation of the services offered by Cell and Gene Therapy Catapult.



Figure 7.1 Cell and Gene Therapy Catapult: Services

Figure 5.2 Represents the service portfolio section in an industry profile

\\172.16.1.2\Natasha		Table	Tools						-
Review View H	elp [Design	Layout	♀ Search					
$\begin{array}{c c} & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\$	↓ ¶	1.	A A	aBbC 1.	1. AA	1.1.1. <i>1</i>	1.1.1.1.	1.1.1.1.	1.1.1.1.
≡≡≡ ‡- ≛-	•	Chapte	er H ¶Fi	gure H l	Level 1	Level 2	Level 3	Level 4	Level 5
Paragraph	G.							Styles	

1.2.3. MANUFACTURING CAPABILITIES

Cell and Gene Therapy Catapult expects to open its fully functional, large-scale GMP manufacturing facility located within the Stevenage Bioscience Catalyst campus in 2017.¹² Stevenage Bioscience Catalyst was established as a joint venture between the Department for Business Innovation and Skills, GSK, the Wellcome Trust and Innovate UK. The facility <u>is</u> <u>considered to be</u> amongst the first few GMP compliant production plants in the UK that provides translational research and development services to pharmaceutical and biotechnology companies.¹³ The GBP 55 million, large-scale GMP cell therapy manufacturing center of Cell and Gene Therapy Catapult is focused on catering to the development needs of late stage clinical candidates. According to the company, the center is likely to support the manufacturing agreement that was recently signed with Cellular Therapeutics for the development of immune cell therapy clinical program.¹⁴ The facility offers space on lease for use to the cell and gene therapy players. This center is likely to offer capabilities for manufacturing products for late-stage clinical studies and for commercialization.

Table 7.2 provides additional details on Cell and Gene Therapy Catapult's facility.

Table 7.2 Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities

Key Features	Stevenage Facility
Year of Founding	201515
Location	Stevenage Bioscience Catalyst, UK ¹⁶
cGMP / GTP compliant	Yes
Services	 Process development Product development and manufacturing
Scale of Operation	Clinical, Commercial
Controlled Environment Rooms (CERs)	Yes
Type of Cells	Autologous and allogenic cells

Figure 5.3Represents the manufacturing capabilities section in an industry profile

NON-INDUSTRY PLAYERS

6.1Chapter Overview

There area number of academic players that areactively involved in the field of cell therapy manufacturing. Apart from making generous contributions, in the form of grants, many non-industry players have extended their support as contract manufacturers as well. The chapter comprises of details of the various facilities established by academic players to provide support (for in house requirements and to other players) in clinical and commercial manufacturing of cell-based therapeutics. Each profile comprises of an overview of the institute / organization, along with a list of key features of its facilities and capabilities, covering information such as its area, infrastructure, regulatory licenses / certifications, equipment used, and its product and / or service portfolio.

The following cell therapy manufacturing facilities have been profiled for this project:

- Center for Cell and Gene Therapy, Baylor College of Medicine, US
- Center of Cell Manufacturing Ireland, National University of Ireland, Ireland
- Clinical Cell and Vaccine Production Facility, University of Pennsylvania, US
- Guy's and St. Thomas GMP Facility, Guy's Hospital, UK
- Laboratory of Cell and Gene Medicine, Stanford University, US
- Molecular and Cellular Therapeutics, University of Minnesota, US
- Newcastle Cellular Therapies Facility, Newcastle University, UK
- Rayne Cell Therapy Suite, King's College London, UK
- Scottish National Blood Transfusion Service, Scottish Centre of Regenerative Medicine, UK
- Sydney Cell and Gene Therapy, Australia

6.2 Example of a Non-Industry Profile: Center of Cell Manufacturing Ireland, National University of Ireland

				No	n-industrj	y players - Sav	red to \\172.16	5.1.2\Natasha				
Maili	ings Review	View	Help	₽ Se	arch							
۶	i≡ • i≡ • i i .•	(=)	 2↓ ¶	1	. A	AaBbC	1.1. A/	1.1.1. <i>1</i>	1.1.1.1.	1.1.1.1.	1.1.1.1.	Aa
-	$\equiv \equiv \equiv \equiv$	\$≣ - ≥	" ⊞ •	C	apter H	1 Figure H	Level 1	Level 2	Level 3	Level 4	Level 5	11
Fai	Parag	graph		G.						Styles		

1.3. CENTRE FOR CELL MANUFACTURING IRELAND, NATIONAL UNIVERSITY OF IRELAND, IRELAND

Immunotherapy Adult Stem Cell Therapy

1.3.1. OVERVIEW

The Centre for Cell Manufacturing Ireland (CCMI) claims to be the first and the only cell manufacturing center to be established in Ireland. It is based at the National Centre for Biomedical Engineering Sciences (NCBES) at the National University of Ireland (NUI), Galway. The CCMI was launched by the Minister for Research and Innovation in January 2014. It was established as a part of the Regenerative Medicine Institute's (REMEDI) initiative to contribute to the development and production of regenerative therapies. The Centre possesses experience in the development and manufacturing of stem cells, which can be used in human clinical trials. The key products developed by the center include human MSCs, which can be used as ATMPs for the treatment of conditions, such as critical limb ischemia (CLI) and osteoarthritis in the knee.¹⁵

The CCMI supports the manufacturing and clinical development of several translational medicines developed by the REMEDI, which is based at the NUI Galway. Researchers at the REMEDI have entered into collaborations with several industry players and other academicians, with the intention of advancing R&D in this field. The facility is funded by the Science Foundation Ireland (SFI).¹⁶

Figure 6.1 Represents the overview section in a non-industry profile

	Non-industry players - Saved to \\172.16.1.2\Natasha												
Mailings	Review	View	Help	Q Search	n								
	1 2 2 3 1 1 1 1 1 1 1	€ →	₽↓	۹ 1.	\mathbf{A}_{ℓ}	AaBbC	1.1. A/	1.1.1. ¹	1.1.1.1.	1.1.1.			
• = =		\$≣ - ⊴	2 - 🔛	- Chapt	er H	1 Figure H	Level 1	Level 2	Level 3	Level			
5	Parac	araph		Es.						Styles			



Figure 6.2 Represents the service portfolio section in a non-industry profile

						Non-indus	try players				°
Review	View	Help	Q	Search							
$\begin{array}{c} 1 \\ 2 \\ 3 \\ 3 \\ \end{array} \\ \end{array} \\ \begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ \end{array} \\ \begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	€≣⇒≣	₽↓	¶	1. A	L/	AaBbC	1.1. A#	1.1.1. <i>1</i>	1.1.1.1.	1.1.1.1.	1.1.1.1.
≡≡	\$≣ - ⊉	2 - 💷 -	-	Chapter I	Н	¶ Figure H	Level 1	Level 2	Level 3	Level 4	Level 5
Parag	Iraph		E.							Styles	

Table 8.2 Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities

Key Features	Description
Year of Establishment	2014 ¹⁹
Location	Galway, Ireland ²⁰
cGMP / GTP compliant	Yes
Scale of Operation	Clinical
Controlled Environment Rooms (CERs)	Yes (6 processing clean rooms)
Product Portfolio	 Adult Stem Cells: Stem cells for the development of ATMPs, MSCs Immunotherapy: T-cells
Type of Cells Manufactured	Autologous, allogeneic and genetically modified cells
Type of Culture	Adherent and suspension culture
Total Area	2,700 sq ft
Accreditations / Licenses Held	HPRA IMP11396/00001 ²¹ HPRA 2015/9013/IMP11396
Experience ²²	 Autologous MSCs for phase Ib trial for transplantation in patients with CLI. Verification of stem cell batches for the treatment of osteoarthritis in a phase II (ADIPOA2) clinical trial. Manufacturing stem cell batches for the treatment of diabetic kidney disease, as a part of the NEPHSTROM project, which was to be undertaken by Orbsen Therapeutics. Manufacturing stem cell batches for the VISICORT clinical trial project, to evaluate the application of stem cells in corneal transplant.
Collaborations	 The facility has entered into collaborations with local and national research institutes and is working on a few international projects as well. Details on some of the initiatives that the facility is currently working on are provided below: Purstem: An EU funded 7th Framework Programme project aimed to create standard approaches and tools for the manufacturing of large numbers of MSCs.²⁴ EuroStemCell: An EU funded 7th Framework Programme project consisting of over 90 European regenerative medicine and stem cell research laboratories, with an aim to spread awareness in society about this novel field of medical science.²⁵

Figure 6.3 Represents the manufacturing capabilities section in a non-industry profile

NON-PROFIT ORGANIZATIONS

7.1Chapter Overview

Several non-profit organizations, academic research centers and other industrial players have continuously supported the development of cell-based therapies in a number of ways. These include funding, assistance in transition to the clinical stage by offering manufacturing services and regulatory guidance. The support from these non-profit organizations has contributed significantly to the growth in the field of cell-based therapies.

7.2Non-Profit Organizations

out	References	Mailings Review View Help		anizations 1234 - Saved to	\\172.16.1.2\Natasha	c (Shivan
		<> I = • I = • 'I = • I = ■ (↓) ▲ • I = = = = ■ (■ • (▲ • □	I . I .	AaBbC 1.1. AA 1 Figure H Level 1	1.1.1. 2 1.1.1.1. Level 2 Level 3		1.1.1. AaBbCcl evel 5 1 Normal	AaBbCcDdEr T Source	AaBbC
ont	Table	9.1 Cell Therapy	Manufac	turing: List	of Non-Pro	styles	anization	18 ^{8, 9}	
	S. No	Organization	Year of Founding	Country	Details				
	1	Foundation of Croatian Association for Regenerative Medicine and Stem Cell Therapy	2015	Croatia	professionals	s from diffe iterest towa	les a platform erent fields wh ards the advan e / stem cell	10 share	
	2	CellCAN	2014	Canada	manufacturii provides a pl	ng facilities atform for t edge and qu	ides cell ther and services the <u>general p</u> peries related nd cellular	It also ublic to	
	3	European Bank for induced pluripotent Stem Cells (<u>EBiSC</u>)	2014	UK	controlled, re	esearch-grad ed services	ess to quality- de iPSC lines to researcher wide. ¹²	, data	
	4	National Cell Manufacturing Consortium (NCMC)	2014	US	The NCMC technologies cost-effectiv therapies by	develops an that can en e manufactu leveraging	nd implement able large-sc uring of cell- currently ava sses in a plan	ale, based ilable	

Figure 7.1 Represents the list of non-profit organizations

7.3Example of a Non-Profit Organization: CellCAN

		СТМ	- Non Profit C	Organizations	1234			
Review View Help	ς	Search						(K)
- \$ → \$ → \$ → \$ → \$ → \$ → \$ → \$ → \$ → \$	¶	1. A:	AaBbC	1.1. A#	1.1.1.	1.1.1.1.	1.1.1.1.	1.1.1.1.
= = 💷 - 🖄 - 🖽	Ŧ	Chapter H	1 Figure H	Level 1	Level 2	Level 3	Level 4	Level 5
Paragraph	E.						Styles	
CellCAN is a non-profit organization that is primarily funded by the Networks of Centres of								

Excellence (NCE) of Canada, the Fondation de l'Hôpital Maisonneuve-Rosemont and other health and educational organizations. These organizations have provided funds worth USD 3 million over a period of four years beginning from September 2014.^{37, 38}

CellCAN aims to bring together players in Canada that manufacture cell and tissue-based therapies. These include those that have facilities capable of manufacturing products for stem cell transplantation, tissue repair and immunotherapy, for use in clinical trials. The organization acts as a platform to support the combining of resources and knowhow of these facilities and encourages stakeholders to advance research and clinical development in regenerative medicine and cell therapy. In addition, the organization intends to promote the expansion (scale-up) of novel manufacturing processes in cell-based therapy. Table 9.2 provides an overview on CellCAN, information on its partners, and capabilities and services.

Parameter	Description
Founding Year	2014 ³⁹
Headquarters	Montreal, Canada ⁴⁰
Network Affiliates	 CellCAN Network Affiliates: Centre of Excellence in Cell Therapy (Maisonneuve-Rosemont Hospital) Orsino Cell Therapy Translational Research Laboratory (Princess Margaret Hospital) Ottawa Hospital Research Institute (University of Ottawa) Alberta Cell Therapy Manufacturing (University of Alberta) Centre of Genomics and Policy (McGill University) Michael Smith Laboratories (University of British Columbia)
Expertise and Services	CellCAN offers the following services: ⁴¹ Manufacturing research and clinical grade stem cells and tissues Support for ethical, legal and regulatory compliance Conducting clinical studies Helping in the submission of regulatory filings

Table 9.2 CellCAN: Overview

Figure 7.2 Represents an overview of a Non-Profit Organization: CellCAN

7.4International Societies

In addition to non-profit organizations, a number of other organizations / societies have made significant contributions to the field of cell-based therapy. These societies have helped in accelerating the growth in this domain by promoting these novel therapies, spreading awareness and providing platforms for researchers, clinicians and other

stakeholders in the industry to come together to discuss future opportunities, therapeutic and commercial potential, and the challenges associated with this field.

- 🗞	lings Review View Help ☷ ▾ ┋☴ ▾ ▫ё☴ ▾ │ ☲☰ ☰ │ ᢓ↓ │ ¶	1. A: AaBbC 1.1. A: 1.1.1. 1 1.1.1.1 1.1.1.1.	1.1.1.1. AaBbCcI
- <u>A</u> -	≡≡≡∎ \$≡• &•⊞•		Level 5 1 Normal
5	Paragraph	Ta Styles	

Table 9.6 Cell Therapy Manufacturing: List of Gene and Cell Therapy Societies

S. No.	Organization / Society
1	American Society of Gene and Cell Therapy
2	Australasian Gene and Cell Therapy Society
3	Austrian Network for Gene Therapy
4	British Society of Gene Therapy
5	European Society of Gene and Cell Therapy
6	Finnish Gene Therapy Society
7	French Society of Cellular and Gene Therapy
8	German Gene Therapy Society
9	International Society for Cancer Gene Therapy
10	Irish Society for Gene and Cell Therapy
11	Israeli Society for Gene and Cell Therapy
12	Japan Society for Gene Therapy
13	Korean Society of Gene and Cell Therapy
14	The Netherlands Society of Gene and Cell Therapy
15	Spanish Society of Gene and Cell Therapy
16	Swedish Society for Gene and Cell Therapy
17	Turkish Society for Gene and Cell Therapy
Source: htt	p://www.genetherapynet.com/societies.html

Figure 7.3 Represents the list of various international gene and cell therapy societies

REGULATORY LANDSCAPE

8.1Chapter Overview

The manufacturing of advanced therapies, such as cell-based therapies and cellular products, is complex and there are a number of challenges associated with their transition from the laboratory to the clinics. Manufacturing facilities and production protocols designed for such product candidates need to undergo strict regulatory checks and comply with stringent standards.

The chapter provides a brief background on the current scenario with respect to regulatory guidelines for the cell therapies. Further, it discusses the challenges related to regulations and finally provides details on the regulatory guidelines for different phases of development.

8.2 Regulatory Systems

Although various regulatory bodies across the globe agree in terms of product safety and quality, there are aspects in which they differ in opinions as well, such as definition / classification of products.Such differences in various geographies make it difficult for cell therapy developers to move from one geographical region to another.

We have also discussed some key attributes with respect to regulatory landscape in cell therapy manufacturing market. It includes:

- Regulatory system in US
- Regulatory system in Europe
- Regulatory system in Japan
- Conditional Approval
- Accreditations in cell therapy manufacturing
- Regulatory Considerations

- Regulatory Landsc				Tab	le Tools							-	
Mailings	Review	View	Help	Design	Lay	out	Q Se	arch					
			2↓ ¶ ≥ - ⊞ -	1.	Az pter H			1.1. A A	1.1.1. A Level 2	1.1.1.1. Level 3	1.1.1.1. Level 4	1.1.1.1. Level 5	AaBbCcI ¶Normal
- Fa	Parag	Iraph		G .							Styles		
Pr	oduct Life	Cycle	P	oints fo	r Con	sidera	ation				Complianc	e Practices	
Pre	eclinical Re D Applicat	esearch i	S: and E	Quality to resea on cell deliver, popular afety The ris be eval All <i>ex</i> v identifi All ant and acc The ch must be An asse- must be All inte taken i fficacy Multipl pharma <i>In vitro</i> All ant taken i i	r must arch de sourcee y meth icion as ks assoc uated vivo mu- ed icipate counter ances of e estim essmer e carrié craction nto acc le para iciologi r result mal str into acc ing pro-	be emi- sign; e, targe lood, ar says occiated anipul d imm d for of tera ated a tt of c ed out ns wit count meter ccal ar s mus udy re count, oduct	sured a this ree et indi nimal i d with lation : and ass ell mig ch conc s must i to eap sults n along efficad	quires acc cation, stu model to b the delives requirement esponses n (ectopic ti sessed gration to n comitant the cological s oppropriatel nust be car with <i>in vit</i>	timed when i urate inform dy dose and e considered ry procedure nust be cons ssue formati non-target re terapies mus ted in the studies y evaluated efully asses ro study dat	t comes nation I and e must idered ion egions at be sed and a while	GLP		
Cli	inical Trial	s		optimiz Route of must be Eligibil as the t Several	ed in t of adm taken lity crit arget p clinic studie	the eau inistra into teria r patient al par	rly pha ation a accour nust b t popul amete	ases nd anatom 11 e defined a lation rs are asse:	of therapy m ic site of de appropriately ssed during they are mor	livery y, such the	GCP, cGMI	P. cGTP.	

Figure 8.1 Represents the regulatory considerations for cell therapies

RECENT DEVELOPMENTS

9.1Chapter Overview

This chapter presents insights on the various partnerships and collaborations related to cell therapy manufacturing that have been inked in the past few years. It also highlights the different types of partnership models that have been adopted by stakeholders in this domain and includes a comprehensive analysis of these partnerships based on various parameters. Overall, it provides an analytical overview of the activity of the various stakeholders in this evolving market.

9.2 Partnerships

Au	toSave 🖲 Off) 🗜 🕤 🗸 🤇	⇒ - ∓			Final co	llaborations - Excel		
File	Home Insert Pa	ge Layout Formulas	Data Review \	/iew Help 🛛 Search				
Paste	Copy -	New Roma • 10 • A A		eb Wrap Text	General •	€ Conditional Format as	Normal	Bad Neutr
*	💉 Format Painter	<u>u</u> • 🗄 • 🕭 • 🗛 •				Formatting • Table •		Neuti
	Clipboard 🕞	Font	Ali	gnment 🕞	Number 🕞		Styles	
B4		<i>f</i> ∗ Company Name	2					
	В	С	D	E	F		G	
4	Company Name	Headquarters	Month &	Partner	Headquarters		f collaborati	on
5	Adaptimmune	Abingdon, Oxfordshire	Jun-16	Thermo Fisher Scientific	Waltham, MA	Additiona Agreemer		
6	Apceth Biopharma	Ottobrunn	Oct-17	DCPrime	Leiden, The Netherlands	Manufact	uring Agreeme	ent
7	Saint-Gobain	Paris, La Défense	Feb-17	Argos Therapeutics	Durham, North Carolina	Manufact	gy Upgrade an uring Process nent and Testin t	
8	Bone Therapeutics	Gosselies, Belgium	Sep-17	Asahi Kasei Corporation	Tokyo, Japan	Manufact	gy Upgrade an uring Process eent and Testin t	
9	Cell Medica	London	Jun-17	Cell and Gene Therapy Catapult	London	Acquisitio		
10	Cell and Gene Therapy Catapult	London	Sep-17	TrakCel	Cardiff, Wales	Additiona Agreemer		
11	Cell Medica	London	Nov-16	Baylor College of Medicine	Houston, Texas	5		
12	Cellular Biomedicine Group (CBMG)	Cupertino, CA	Nov-17	Thermo Fisher Scientific Ltd. (China)	Shanghai	Manufact	gy Upgrade an uring Process uent and Testin t	
	Cellular Biomedicine	Cupertino, CA	Apr-17	GE Healthcare Life	China		gy Upgrade ai	nd
4	CTM 1.0 Ad	ditions Expansion	+		1	Y	: •	[

Figure 9.1 Provides informationon collaborations / partnerships of key industry players

9.3 Expansions

		₽ \$• °· •			Final co	ollaborations - Excel
ile	Home	Insert Page Layout	Formulas Data	Review View Help 🛛 S	earch	
	K Cut Copy →	Times New Roma		_ /	General -	Normal Ba
te	؇ Format Pa	inter B I U -	• 🏠 • 🗛 • 📰 🗏	🗄 🚍 🚈 🗮 🖽 Merge & Cente	r ▼ 🍄 ~ % 🔹 號 🔐	Conditional Format as Formatting + Table +
	Clipboard	r₂ Font	- G	Alignment	na Number na	Styles
	-	$\times \checkmark f_x$	1			
	А	В	С	D	E	F
5	8. No.	Company Name	Month & Year	Area	Current / Future	Summarize
	1	3P Biopharmaceuticals	Jun-17	5 new stability chambers	Current	Expansion of its GMP stability study capabilities
2	2	Batavia Bioservices	Oct-17			Expansion of its GMP clean room facilities
2	3	Brammer Bio	Sep-17	clinical capacity expansion, installed a state-of-the-art isolator and integrated fill line for drug product manufacturing	Completion g	
2	4	Cellular Biomedicine Group (CBMG)	Nov-17	100,000-square-foot space with a top-of-the-line GMP facility; launch of the "CBMG- GE Joint Laboratory of Cell Therapy"; total GMP capacity of 70,000 square feet		Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Join Laboratory
4	5	Cellular Biomedicine Group (CBMG)	Mar-17	expanded 30,000 square foot facility	Completion	20,000 square feet of the Wuxi GMP facility will be dedicated to advanced stem cell culturing, centralized plasmid and viral vector production, cell banki and development of reagents.
)	5	EUFETS (BioNTech Innovative Manufacturing Services)		doubling cleanroom space and expanding development and quality control areas in a new facility	Future	Expands Production Capacities
4		TM 1.0 Additions	Expansion (+)		F .	

Figure 9.2 Provides information on expansion that the industry is undergoing for manufacturing of cell therapies

The collection of all these information on partnerships and expansions help the analyst to get an idea if the field is evolving or mature, research oriented or industry oriented and makes the report more impactful. It also helps the clients to identify potential collaborators and competitors and also allows researchers to focus on niche areas.

PRIMARY RESEARCH

10.1 Overview

The data presented in the report has been gathered via secondary and primary research. For all the projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The interviews conducted with experts are scripted down and forms the important part of the project report. The information provided by the experts help a lot in validating the data as well as provide deeper insights of the project. For cell therapy manufacturing market project, we have conducted an interview with formula pharmaceuticals and scripted it down to present it in a form of a transcript in the report. In this process, the expert shares some key insights about the field and his opinion regarding the future market of the field. Once the discussion is over, a transcript is prepared that is send back to the expert for his permission and then after the transcript is included in the respective report.

10.2Interview Contacts

This was done to capture data that was to be used to conduct interviews with experts in this domain (academia, industry, medical practice and other associations). For this a database was prepared, including the contacts of all the main personnel of a company. Post gathering the desired data, interview requests were sent to the concerned person. These interviews form a part of primary research that is pivotal to have deeper insights of the project. Further, this information helps us to understand the emerging trends in the market. Additionally, it aids in validating our own understanding of the domain, how the market is likely to shape up across different regions and technology segments in the coming future.

In addition, the contacts captured in the interview contact database / contact list were contacted and requested to respond to the survey which contained questions regarding the various manufacturing parameters. This exercise was a part of primary research and thus help us to understand the market in a much better way. We can also confirm and validate the parameters through the survey responses that were initially captured in the main database.

চি হ			C	Contact list formatted - Excel
Insert Pag	ge Layout Formulas Dat	a Review View H	lelp 🛛 Search	
Calibri	• 11 • A A =	≡ <u>=</u> ≫ - ĕb w	rap Text General	✓ I Normal Bad
nter B I	<u>u</u> • 🗄 • 🕭 • 🗛 • 🗄	= = = •= •= = M	erge & Center 👻 🍄 🔹 % 🔹	Conditional Format as Good Neut Formatting ▼ Table ▼
G	Font 🕞	Alignment	ា Number	Ta Styles
× ✓	fx			
В	С	D	G	Н
8.No.	Organization Name	Industry / Non- Industry	Name	Designation
1	Adaptimmune	Industry	Mark Dudley	Senior Vice President, Bioprocessing & Development CMC, Technical Operations
2	Adaptimmune	Industry	James Noble	CEO
3	Adaptimmune	Industry	John Lunger	Vice President, Manufacturing and Supply Chain
4	Apceth Biopharma	Industry	Christine Guenther	CEO & Medical Director
5	Bavarian Nordic	Industry	Cesar Pico-Navarro	Vice President, ImmunoOncology Clinical Strategy
6	Bellicum Phamaceuticals	Industry	Alan Smith	Executive Vice President, Technical Operation
7	Bellicum Phamaceuticals	Industry	Matthew Hewitt	Principal Scientist/Director - Tumor Microenvironment
8	Bone Therapeutics	Industry	Carmen Brenner	QC Manager
9	Bone Therapeutics	Industry	Benoit Champluvier	Chief Technology and Manufacturing Office
10	Bone Therapeutics	Industry	Miguel Forte	Chief Medical Officer
11	Cancer Research UK, BDU	Non-Industry	Heike Lentfer	Head of Biotherapeutics Development & Dr Supply
12	Catapult	Industry	Stephen Ward	COO
13	<u>Catapult</u>	Industry	Jon Halling	Quality Director
14	Catapult	Industry	James Biggins	Manufacturing Centre Director
15	CCRM	Non-Industry	Emily Titus	Director, Technology Development
16	Cell Medica	Industry	Alex Bloom	Vice President / Director Global Regulatory

Figure 10.1Highlights the various contacts of the key industry / non-industry players

			Formula P	harn	naceuticals_	Transcript-PL-	SG Edit - Rea	ıd-Only - Sav	ed to this PC		· _	
ngs	Review	View	Help	Q	Search							0
Ξ-	$\frac{1}{2}$ $+$ $\frac{1}{3}$ $+$ $\frac{1}{3}$ $+$	€≣ →≣	≣ 2 ↓ ¶	Г	1. A.	AaBbC	1.1. A#	1.1.1.	1.1.1.1.	1.1.1.1.	1.1.1.1.	AaBb
= =		\$≣ - ≤	" ≣ •		Chapter H	¶ Figure H	Level 1	Level 2	Level 3	Level 4	Level 5	1 Nor
	Parag	graph		Fail -						Styles		
	INTERV	IFW T	RANSC	RIP	т							

INTERVIEW TRANSCRIPT VIDAL DE LA CRUZ VICE PRESIDENT OF PRECLINICAL R&D FORMULA PHARMACEUTICALS

Roots Analysis: Can you tell us more about the allogenic cytokine induced killer (CIK) CAR-T therapies that Formula Pharmaceuticals is developing against various oncological disorders? How are these products different from the conventional CAR-T therapies?

Formula Pharmaceuticals: The CIK cell is a cell type that does not exist in the body. These CIK cells are generated *ex-vivo* through the *in-vitro* treatment of polymorphonuclear cells with interferon gamma and anti CD3 antibody propagation. <u>During the course of</u> this treatment, T-cells develop the characteristics of natural killer (NK) cells as well as acquire different phenotypes. Generally, T-cells are typically CD3+ and CD56-, NK cells are CD3- and CD56+, and the cytokine induced killer cells are both CD3 and CD56+. There are many other phenotypic differences showing that these cells have both T-cell and NK cell characteristics. Due to this, we believe that the CIK cell is a very good effector cell type to use for CAR type therapy. One of the interesting aspects of these cells is that, in addition to being a very good cytotoxic killer cells, they also have the propensity to decrease the incidence and severity of graft versus host disease (GvHD), which is a big challenge when it comes to allogenic treatments.

Currently, most of the therapies are being evaluated as autologous cell treatments. However, a lot of research effort is being put to develop allogenic treatments, primarily using NK cells. Similar approaches can be used with the CIK cells as being carried out with NK cells. One of the

Figure 10.2Represents the Interview Transcript for cell therapy manufacturing market project

ADDITIONAL PROJECTS

11.1Gene Therapy

In addition to my project, I have also contributed in another project namely, Gene Therapy. Following section represents the work that I have been done in this project.

11.1.1Collecting KOLs

Mostly KOLs form a part of drug-based projects where information on key opinion leaders are collected which includes name of the company, product name, phase of the product,name of the investigator and their e-mail id's.

	💷 🗄 জন্ 🖓 👳			Fina	al Gene therapy KOL 2 Read-C	Inly - Excel	
н	ome Insert Page Layout	Formulas Data Review N	/iew Hel	p 🛛 Search			
• • • •	py * mat Painter	$\begin{array}{c c} 10 & A^* & A^* \end{array} \equiv \equiv = & \gg \cdot \\ \hline & & & & & \\ \bullet & & & & \\ \bullet & & & & \\ \bullet & & & &$		ge & Center 🝷 🍹 %	2	able	↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
Clipboa			gnment	ra Num	iber 🕞	Styles	
A	▼ : × ✓ f _x s	C.	D	E	F	G	
S.No	Product Name	Company	Phase	Name of the investigator	Designation	E-mail id	
1	OTL-101	Orchard Therapeutics, University of California, Los Angeles and University College London / Great Ormond Street Hospital	II/III	Donald B. Kohn	Professor	dkohn@mednet.ucla.edu	
2	Toca 511 (vocimagene amiretrorepvec) + Toca FC	Tocagen	II/III	Timothy Cloughesy	Director	tcloughesy@mednet.ucla.edu	
3	AVXS-101	AveXis, RegenX Biosciences	Ш	Jerry R Mendell	Neurologist	http://www.nationwidechildrens. mendell	org/jerry-r-
4	Lenti-D	bluebird bio	II/III	David Williams	President	http://www.childrenshospital.org id-williams	/doctors/day
				Christine Duncan	Assistant Professor of Pediatrics	http://www.childrenshospital.org id-williams	/doctors/day
				Satiro de Oliveira	Clinical Instructor	SDeOliveira@mednet.UCLA.edu sndeoliveira@ucla.edu	1,
5	E10A	Marsala Biotech, Guangzhou Double Bioproducts	ш	Huiqiang Huang	Professor	Huangpeng@sysucc.org.cn	
6	GS010	Gensight Biologics	ш	Nancy J. Newman	Instructor	nancy.newman@emory.edu	
				Patrick Yu Wai Man	Honorary Consultant Ophthalmologist		

Figure 11.1 Represents the list of Key Opinion Leaders engaged in the field of gene therapy

11.1.2Short Profiling of key industry players

			Int	erview Compa	ny Profiles -	Read-Only -	Saved to this	РС		
Review	View	Help	Ç	Search						(K)
$\frac{1}{2} = + \frac{1}{2} = +$	€≣→≣	₽↓	T	1. A:	1.1. AA	1.1.1.	1.1.1.1.	1.1.1.1.	1.1.1.1.	AaBbCcI
	\$≣ - ⊉		*	Chapter H	¶ Level 1	1 Level 2	1 Level 3	1 Level 4	1 Level 5	1 Normal 1
Parag	graph		E.						Styles	

1. CHAPTER HEADING

Company Name: Hemera Biosciences

Company Particulars	Specifications
Year of Establishment	2010
Headquarters	Boston, US ¹
Company Overview	Hemera Biosciences is a clinical stage company focused on developing gene therapy for retinal diseases. ²
Product Pipeline	The company's pipeline consists of the following product: ³ • HMR59 (Phase I, dry age-related macular degeneration)
Other Important Details	 In December 2016, the company received approval from the USFDA to advance HMR59 into clinics.⁴

Company Name: Milo Biotechnology

Company Particulars	Specifications
Year of Establishment	2012 ⁵
Headquarters	Cleveland, US ⁶
Company Overview	Milo Biotechnology is a clinical stage company focused on developing gene therapies to strengthen the muscles and avoid muscle atrophy. 7
Product Pipeline	 The company's pipeline comprises of the following products:⁸ AAV1-FS344 (Phase I/II, Duchenne muscular dystrophy, Becker muscular dystrophy, Inclusion body myositis)
Technology Overview	The company's technology has been exclusively licensed from Nationwide Children's Hospital. The company's technology is based on the delivery of follistatin through AAV vectors as a single dose. Follistatin blocks the TGF-β family ligands to prevent fibrosis and increase the muscle strength by blocking the proteins that activate the signaling pathways for reducing the muscle mass and strength. The technology exhibited positive results in the case of mice, macaques. ^{9,10}

Figure 11.2 Represents the brief profiling of two industry players engaged in the field of gene therapy

11.2Undruggable Cancer Targets

In this project, I worked on two new representations:

11.2.1 Bulls Eye




Figure 11.3 Bulls Eye Representation




Figure 11.4 Regional Analysis

REFERENCES

- 1. https://www.rootsanalysis.com/about-us.html
- 2. http://www.asgct.org/general-public/educational-resources/gene-therapy-and-cell-therapy-defined
- 3. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PD F
- 4. http://www.acgt.com/talks/pdfs/Manufacturing%20Cell%20and%20Gene%20Therapy%20Pro ducts%20-%20GE%20Healthcare.pdf
- 5. http://www.futuremedicine.com/doi/full/10.2217/rme.14.73
- 6. http://cellmanufacturingusa.org/sites/default/files/NCMC_Roadmap_021816_hi gh_res-2.pdf
- 7. https://www.bioindustry.org/uploads/assets/uploaded/b4b17370-d4e6-42f7-af03d7ad0f9fb382.pdf